In generalized myasthenia gravis (gMG), the therapeutic rationale for complement C5 inhibition is grounded in a well-defined immunopathological cascade.
Immunoglobulins are the central effector molecules of adaptive humoral immunity. They are produced by B cells and their terminally differentiated plasma cells and contribute to pathogen clearance, maintenance of immune homeostasis, and the development of immunopathology through a dual ...
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
